These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 15555766)
1. Glycogen synthase kinase-3 is increased in white cells early in Alzheimer's disease. Hye A; Kerr F; Archer N; Foy C; Poppe M; Brown R; Hamilton G; Powell J; Anderton B; Lovestone S Neurosci Lett; 2005 Jan; 373(1):1-4. PubMed ID: 15555766 [TBL] [Abstract][Full Text] [Related]
2. Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. Hampel H; Ewers M; Bürger K; Annas P; Mörtberg A; Bogstedt A; Frölich L; Schröder J; Schönknecht P; Riepe MW; Kraft I; Gasser T; Leyhe T; Möller HJ; Kurz A; Basun H J Clin Psychiatry; 2009 Jun; 70(6):922-31. PubMed ID: 19573486 [TBL] [Abstract][Full Text] [Related]
4. Delayed rather than decreased BOLD response as a marker for early Alzheimer's disease. Rombouts SA; Goekoop R; Stam CJ; Barkhof F; Scheltens P Neuroimage; 2005 Jul; 26(4):1078-85. PubMed ID: 15961047 [TBL] [Abstract][Full Text] [Related]
5. Plasma aminothiol compounds, but not serum tumor necrosis factor receptor II and soluble receptor for advanced glycation end products, are related to the cognitive impairment in Alzheimer's disease and mild cognitive impairment patients. Hernanz A; De la Fuente M; Navarro M; Frank A Neuroimmunomodulation; 2007; 14(3-4):163-7. PubMed ID: 18073509 [TBL] [Abstract][Full Text] [Related]
6. Cerebrospinal fluid neuron-specific enolase: a further marker of Alzheimer's disease? Palumbo B; Siepi D; Sabalich I; Tranfaglia C; Parnetti L Funct Neurol; 2008; 23(2):93-6. PubMed ID: 18671910 [TBL] [Abstract][Full Text] [Related]
7. Increased CSF-BACE 1 activity is associated with ApoE-epsilon 4 genotype in subjects with mild cognitive impairment and Alzheimer's disease. Ewers M; Zhong Z; Bürger K; Wallin A; Blennow K; Teipel SJ; Shen Y; Hampel H Brain; 2008 May; 131(Pt 5):1252-8. PubMed ID: 18334538 [TBL] [Abstract][Full Text] [Related]
10. Dysfunction of protein kinase FA/GSK-3 alpha in lymphocytes of patients with schizophrenic disorder. Yang SD; Yu JS; Lee TT; Yang CC; Ni MH; Yang YY J Cell Biochem; 1995 Sep; 59(1):108-16. PubMed ID: 8530529 [TBL] [Abstract][Full Text] [Related]
11. Both plasma retinol-binding protein and haptoglobin precursor allele 1 in CSF: candidate biomarkers for the progression of normal to mild cognitive impairment to Alzheimer's disease. Jung SM; Lee K; Lee JW; Namkoong H; Kim HK; Kim S; Na HR; Ha SA; Kim JR; Ko J; Kim JW Neurosci Lett; 2008 May; 436(2):153-7. PubMed ID: 18378077 [TBL] [Abstract][Full Text] [Related]
12. Alzheimer-like changes in protein kinase B and glycogen synthase kinase-3 in rat frontal cortex and hippocampus after damage to the insulin signalling pathway. Salkovic-Petrisic M; Tribl F; Schmidt M; Hoyer S; Riederer P J Neurochem; 2006 Feb; 96(4):1005-15. PubMed ID: 16412093 [TBL] [Abstract][Full Text] [Related]
13. Hippocampal metabolic abnormalities in mild cognitive impairment and Alzheimer's disease. Ackl N; Ising M; Schreiber YA; Atiya M; Sonntag A; Auer DP Neurosci Lett; 2005 Aug 12-19; 384(1-2):23-8. PubMed ID: 15905028 [TBL] [Abstract][Full Text] [Related]
14. Glycogen synthase kinase-3 regulation of chromatin segregation and cytokinesis in mouse preimplantation embryos. Acevedo N; Wang X; Dunn RL; Smith GD Mol Reprod Dev; 2007 Feb; 74(2):178-88. PubMed ID: 16941690 [TBL] [Abstract][Full Text] [Related]
15. Peripheral levels of glutathione and protein oxidation as markers in the development of Alzheimer's disease from Mild Cognitive Impairment. Bermejo P; Martín-Aragón S; Benedí J; Susín C; Felici E; Gil P; Ribera JM; Villar AM Free Radic Res; 2008 Feb; 42(2):162-70. PubMed ID: 18297609 [TBL] [Abstract][Full Text] [Related]
16. Differences of peripheral inflammatory markers between mild cognitive impairment and Alzheimer's disease. Bermejo P; Martín-Aragón S; Benedí J; Susín C; Felici E; Gil P; Ribera JM; Villar AM Immunol Lett; 2008 May; 117(2):198-202. PubMed ID: 18367253 [TBL] [Abstract][Full Text] [Related]
17. CSF biomarkers for mild cognitive impairment and early Alzheimer's disease. Andreasen N; Blennow K Clin Neurol Neurosurg; 2005 Apr; 107(3):165-73. PubMed ID: 15823670 [TBL] [Abstract][Full Text] [Related]
18. Increased platelet GSK3B activity in patients with mild cognitive impairment and Alzheimer's disease. Forlenza OV; Torres CA; Talib LL; de Paula VJ; Joaquim HP; Diniz BS; Gattaz WF J Psychiatr Res; 2011 Feb; 45(2):220-4. PubMed ID: 20576277 [TBL] [Abstract][Full Text] [Related]
19. [Therapy of Alzheimer disease]. Kovács T Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816 [TBL] [Abstract][Full Text] [Related]
20. Automated Neuropsychological Test Battery (CANTAB) in mild cognitive impairment and in Alzheimer's disease. Egerházi A; Berecz R; Bartók E; Degrell I Prog Neuropsychopharmacol Biol Psychiatry; 2007 Apr; 31(3):746-51. PubMed ID: 17289240 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]